Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 16/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 8/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242593 | 0.91 | LTB4R2 (0.44) | LTB4R2AGTR1AGTR2ABCB11GP6 | |
| SCHEMBL3124967 | 0.91 | LTB4R2 (0.44) | LTB4R2AGTR1AGTR2ABCB11GP6 | |
| SCHEMBL2969533 | 0.90 | PTGES (0.42) | LTB4R2AGTR1PTGESABCB11GP6 | |
| SCHEMBL3112807 | 0.88 | LTB4R2 (0.47) | LTB4R2AGTR1AGTR2 | |
| SCHEMBL3117096 | 0.87 | HDAC6 (0.56) | LTB4R2AGTR1AGTR2 | |
| SCHEMBL3122148 | 0.87 | AGTR1 (0.42) | LTB4R2AGTR1AGTR2ABCB11GP6 | |
| SCHEMBL3122151 | 0.87 | AGTR1 (0.42) | LTB4R2AGTR1AGTR2ABCB11GP6 | |
| SCHEMBL3116176 | 0.86 | LTB4R2 (0.47) | LTB4R2AGTR1AGTR2 | |
| SCHEMBL3124004 | 0.86 | LTB4R2 (0.41) | LTB4R2AGTR1AGTR2 | |
| SCHEMBL2969524 | 0.86 | PTGES (0.42) | AGTR1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673889-B2 | BLT2-mediated disease, BLT2 binding agent and the compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2172222-A2 | Novel BLT2-mediated disease, BLT2-binding agent and compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1745800-A1 | NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | MALT1, SLC10A2, LCP2 | LTB4R2 66/4885AGTR1 996/4885AGTR2 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.